Cargando…

The Correlation between the Use of the Proton Pump Inhibitor and the Clinical Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

BACKGROUND: To determine if the use of the Proton Pump Inhibitors (PPI) impacts the clinical efficacy of Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC), a meta-analysis was conducted. METHOD: Eleven studies from PubMed, EMBASE, Cochrane Library, Web of Science, and other d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Da-Hai, Wong, Wan-Ching, Zhou, Jia-Xin, Luo, Ji, Cai, Song-Wang, Zhou, Hong, Tang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288308/ https://www.ncbi.nlm.nih.gov/pubmed/35855807 http://dx.doi.org/10.1155/2022/1001796

Ejemplares similares

Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer
por: Qin, Bao-Dong, et al.
Publicado: (2021)

Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors
por: Giordan, Quentin, et al.
Publicado: (2021)

Immune checkpoint inhibitors and their interaction with proton pump inhibitors–related interstitial nephritis
por: Miao, Jing, et al.
Publicado: (2023)

Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Dar, Sophia, et al.
Publicado: (2022)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics
por: Revaiah, Pruthvi C, et al.
Publicado: (2018)

Comparison of the Efficacy of Polaprezinc Plus Proton Pump Inhibitor and Rebamipide Plus Proton Pump Inhibitor Treatments for Endoscopic Submucosal Dissection-induced Ulcers
por: Jung, Da Hyun, et al.
Publicado: (2021)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis
por: Lopes, Sébastien, et al.
Publicado: (2023)

An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis
por: Liu, Chaoxing, et al.
Publicado: (2022)

The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
por: Chang, Yu, et al.
Publicado: (2022)

Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence
por: Mistry, Suresh D., et al.
Publicado: (2011)

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
por: Kawachi, Hayato, et al.
Publicado: (2023)

The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Li, Chao, et al.
Publicado: (2020)

Effect of Proton Pump Inhibitors on Colorectal Cancer
por: Sasaki, Takamitsu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
por: Tomita, Yusuke, et al.
Publicado: (2022)

Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux
por: Liu, C., et al.
Publicado: (2016)

Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia
por: Wauters, Lucas, et al.
Publicado: (2021)

A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma
por: Homicsko, Krisztian, et al.
Publicado: (2022)

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors
por: Duan, Zhihui, et al.
Publicado: (2022)

Anti-infective properties of proton pump inhibitors: perspectives
por: da Rosa, Taciéli Fagundes, et al.
Publicado: (2021)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Use of proton pump inhibitor may be associated with progression of cerebral small vessel disease
por: Kang, Min Kyoung, et al.
Publicado: (2022)

The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors
por: Zhou, Jiaxin, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?
por: Tan, Hui Zhuan, et al.
Publicado: (2023)

The correlation between the influencing factors and efficacy of immune checkpoint inhibitor therapy: an umbrella meta-analysis of randomized controlled trials
por: Hu, Dahai, et al.
Publicado: (2023)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gd4aqtkj44hg30to7m98l2ko84